Soleno Therapeutics, Inc. (SLNO) Tops Q4 EPS by 19c

Soleno Therapeutics, Inc. (NASDAQ: SLNO) reported Q4 EPS of $0.80, $0.19 better than the analyst estimate of $0.61. Revenue for the quarter came in at $91.73 million versus the consensus estimate of $82.45 million.

For earnings history and earnings-related data on Soleno Therapeutics, Inc. (SLNO) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• XORTX to voluntarily delist from TSX Venture Exchange
• Ticketplus files for IPO with shares priced between $13-$15